Taiwan: GLP1RAs Tied to Greater Risk of Diabetic Retinopathy Progression Than SGLT2is
In patients with diabetes and established diabetic retinopathy (DR), treatment with glucagon-like peptide 1 receptor agonists (GLP1RAs) is associated with increased risks of DR progression compared with sodium-glucose cotransporter 2 inhibitors (SGLT2is), according to a study published online July 19 in Diabetes, Obesity and Metabolism.
Donna Shu-Han Lin, M.D., from Shin Kong Wu Ho-Su Memorial Hospital in Taipei, Taiwan, and colleagues examined the effects of GLP1RAs and SGLT2is on the development or progression of DR. Analysis included 1,517 patients treated with a GLP1RA with DR and 9,549 without DR and 3,034 patients treated with an SGLT2i with DR and 19,098 without DR.
Source: Advances and More licensed by HealthDay
